Effects of the GnRH agonist leuprorelin on liver volume in premenopausal women with severe polycystic liver disease.

What Was Tested

This randomized controlled trial looks at Gonadorelin and Leuprolide.

Polycystic liver disease (PLD) is characterized by multiple liver cysts, sometimes leading to severe liver enlargement, with associated physical and psychosocial complaints.

Estrogens may therefore be a target for therapy.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, women only.

In this prospective, open-label study, premenopausal women aged 18-45 years with severe PLD were randomized 1:1 to a direct start of the gonadotropin-releasing hormone agonist leuprorelin (n=6) or to standard care with delayed start of leuprorelin 18 months after randomization (n=8).

Secondary outcomes comprised quality of life, menopausal side effects, and adverse events.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Because people in this Gonadorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Gonadorelin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The primary outcome was liver growth rate at 18 months.

An interim analysis was performed when all participants had reached month 18, as notable side effects were expressed.

What Was Measured

Topics PubMed links to this paper include Leuprolide, Liver Diseases, Liver, Premenopause, Gonadotropin-Releasing Hormone, Cysts and Organ Size.

The authors tagged it with the keywords GnRH agonist, PLD, estrogens, leuprorelin and liver volume.

What This Means in Plain Language

The paper is a randomized and open-label study of Gonadorelin and Leuprolide.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Hepatology communications), a journal based in United States.

More context: the Gonadorelin compound page and the Leuprolide compound page, all human trials.